Literature DB >> 30155621

Fibroblasts and Osteoblasts in Inflammation and Bone Damage.

Jason D Turner1, Amy J Naylor2, Christopher Buckley2,3, Andrew Filer2, Paul-Peter Tak4.   

Abstract

This review discusses the important role fibroblasts play in the process of inflammation and the evidence that these cells may drive the persistence of inflammation. Fibroblasts are key components of the stroma normally involved in maintenance of extracellular matrix and tissue function; however, the term 'fibroblast' is used to describe a heterogeneous population of cells that vary in phenotype both between and within anatomical sites. Fibroblasts possess Toll-like receptors allowing them to respond to pathogen and damage-related signals by producing proinflammatory mediators such as IL-6, PGE2, and GM-CSF and can produce a range of chemokines such as CXCL12, CXCL13, and CXCL8 which attract B and T lymphocytes, monocytes, and neutrophils to sites of inflammation. Interactions between leukocytes and fibroblasts can facilitate increased survival of the leukocytes and modulate phenotypes leading to differential gene expression in the presence of mediators involved in inflammation. Fibroblasts also contribute to collateral tissue damage during inflammation through the production of members of the metalloproteinase family and cathepsins and also through induction of osteoclastogenesis leading to increased bone resorption rates. In persistent diseases, fibroblasts obtain an imprinted, aggressive phenotype leading to the production of higher basal levels of proinflammatory cytokines and the ability to damage tissue in the absence of continual stimuli. This aggressive phenotype offers an attractive new target for therapeutics that could help alleviate the burden of persistent inflammation.

Entities:  

Keywords:  Epigenetics; Fibroblast; Osteoblast; Rheumatoid arthritis; Stromal immunology; Synovial fibroblast

Mesh:

Year:  2018        PMID: 30155621     DOI: 10.1007/978-3-319-78127-3_3

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  6 in total

1.  In vitro effect of low-level laser therapy on the proliferative, apoptosis modulation, and oxi-inflammatory markers of premature-senescent hydrogen peroxide-induced dermal fibroblasts.

Authors:  Daíse Raquel Maldaner; Verônica Farina Azzolin; Fernanda Barbisan; Moisés Henrique Mastela; Cibele Ferreira Teixeira; Alexandre Dihel; Thiago Duarte; Neida Luiza Pellenz; Luiz Fernando Cuozzo Lemos; Carla Maria Uggeri Negretto; Ivana Beatrice Mânica da Cruz; Marta Maria Medeiros Frescura Duarte
Journal:  Lasers Med Sci       Date:  2019-02-02       Impact factor: 3.161

2.  Single-Cell Sequencing Unveils the Heterogeneity of Nonimmune Cells in Chronic Apical Periodontitis.

Authors:  Xinwei Lin; Danlu Chi; Qingzhen Meng; Qimei Gong; Zhongchun Tong
Journal:  Front Cell Dev Biol       Date:  2022-02-10

3.  hTERT-immortalized gingival fibroblasts respond to cytokines but fail to mimic primary cell responses to Porphyromonas gingivalis.

Authors:  Katarzyna B Lagosz-Cwik; Aleksandra Wielento; Weronika Lipska; Malgorzata Kantorowicz; Dagmara Darczuk; Tomasz Kaczmarzyk; Susan Gibbs; Jan Potempa; Aleksander M Grabiec
Journal:  Sci Rep       Date:  2021-05-24       Impact factor: 4.379

4.  Inhibition of PAD4 mediated neutrophil extracellular traps prevents fibrotic osseointegration failure in a tibial implant murine model : an animal study.

Authors:  Emile-Victor Kuyl; Fei Shu; Branden R Sosa; Juan D Lopez; Di Qin; Tania Pannellini; Lionel B Ivashkiv; Matthew B Greenblatt; Mathias P G Bostrom; Xu Yang
Journal:  Bone Joint J       Date:  2021-07       Impact factor: 5.385

5.  METTL3 Regulates Osteoblast Differentiation and Inflammatory Response via Smad Signaling and MAPK Signaling.

Authors:  Yiwen Zhang; Xiaofei Gu; Di Li; Luhui Cai; Qiong Xu
Journal:  Int J Mol Sci       Date:  2019-12-27       Impact factor: 5.923

6.  Ankylosis progressive homolog upregulation inhibits cell viability and mineralization during fibroblast ossification by regulating the Wnt/β‑catenin signaling pathway.

Authors:  Xindong He; Yongqiang Dong
Journal:  Mol Med Rep       Date:  2020-10-11       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.